Kristi Ernandez
Family · Rock Hill, SCNPI 1679045017
Payments from drug & device makers
Across 351 payments — averaging $15.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- Neurocrine Biosciences, Inc.$998
- Teva Pharmaceuticals USA, Inc.$803
- Johnson & Johnson$598
- AbbVie$464
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$460
- plus $1K from 8 others
What the payments were for
- Food & beverage$5,524100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 66 | $1,136 |
| Neurocrine Biosciences, Inc. | 73 | $998 |
| Teva Pharmaceuticals USA, Inc. | 59 | $803 |
| Johnson & Johnson | 37 | $598 |
| AbbVie | 36 | $464 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $460 |
| Alkermes, Inc. | 17 | $338 |
| E.r. Squibb & Sons, L.L.C. | 18 | $276 |
| Vanda Pharmaceuticals Inc. | 8 | $132 |
| Indivior Inc. | 6 | $101 |
| Lundbeck LLC | 6 | $91 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $69 |
| Noven Therapeutics, LLC | 3 | $42 |
| Axsome Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,524 in reported general payments places this provider in the 90th percentile of 3,248 family providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 59 | $190,568 |
| IngrezzaValbenazine Tosylate | 21 | $176,619 |
| VraylarCariprazine Hcl | 75 | $108,322 |
| RexultiBrexpiprazole | 40 | $64,028 |
| Abilify MaintenaAripiprazole | 22 | $63,516 |
| LybalviOlanzapine/Samidorphan Malate | 21 | $35,828 |
| TrintellixVortioxetine Hydrobromide | 49 | $30,124 |
| CaplytaLumateperone Tosylate | 12 | $27,198 |
| Aripiprazole | 92 | $6,508 |
| Atomoxetine Hcl | 19 | $3,175 |
| Buspirone Hcl | 122 | $2,644 |
| Duloxetine Hcl | 104 | $2,631 |
| Hydroxyzine Pamoate | 103 | $2,410 |
| Lurasidone Hcl | 34 | $1,736 |
| Oxcarbazepine | 21 | $1,728 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $598 | $190,56859 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $998 | $176,61921 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,136 | $127,54462 claims |
| AbbVieVraylar | $464 | $108,32275 claims |
| Alkermes, Inc.Lybalvi | $338 | $35,82821 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $69 | $30,12449 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $460 | $27,19812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,248 family providers in South Carolina.
Other family in Rock Hill
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
- Carrie HendersonGreenville$91K
- Sarah ValerioGreer$76K
- Mary WilliamsColumbia$67K
- Michelle StrongGreenville$55K
- Karen McKerihanSummerville$54K
- Doris ReidSimpsonville$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.